Abstracts tagged "antiphospholipid syndrome"

Abstract Number: 1399 • ACR Convergence 2025
Significance of Antiphospholipid Antibodies in Patients with Sjogren’s Disease
Rashmi Thimmapuram¹, Ahmad Alkhatib², Joshua Baker³, Mehrdad Maz⁴ and Ghaith Noaiseh², ¹University of Kansas Medical Center, Westwood, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Pennsylvania, Philadelphia, PA, ⁴The University of Kansas Medical Center, Kansas City, KS
Background/Purpose: A few reports have evaluated the frequency of antiphospholipid antibodies (aPL) in Sjogren’s disease (SjD) and their association with SjD or Antiphospholipid Antibody Syndrome…
Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Santiago Dans Caballero¹, Massimo Radin², Chary López pedrera³, MARIA ANGELES AGUIRRE ZAMORANO⁴, Christian Merlo-Ruiz⁵, Ismael Sanchez-Pareja⁴, Irene Cecchi⁶ and Savino Sciascia⁷, ¹Reina Sofia University Hospital, Lebrija, Andalucia, Spain, ²University of Turin, Turin, Turin, Italy, ³Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁴Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁵Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Córdoba, Spain, ⁶University of Turin, Turin, Piemonte, Italy, ⁷University of Turin, Torino, Italy
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…
Abstract Number: 0123 • ACR Convergence 2025
Prognosis of Cardiac Involvement in Antiphospholipid Syndrome
Juliette Guiraud Chaumeil¹, david saadoun², Laurent Alric¹, Laurent Sailler¹, Sébastien De Almeida Chaves¹, Olivier Lairez¹, Patrice CACOUB³ and Grégory Pugnet⁴, ¹CHU Toulouse, Toulouse, France, ²APHP, neuilly sur seine, France, ³Sorbonne Université, Paris, France, ⁴CHU Toulouse Rangueil Service de Medecine Interne et Immunologie Clinique, Toulouse, France
Background/Purpose: Cardiac involvement in antiphospholipid syndrome (APS) includes valvular, coronary, and myocardial manifestations. Valvular involvement is the most frequent, affecting approximately 30% of patients, while…
Abstract Number: 1299 • ACR Convergence 2025
Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Rasha Elrefai, Marietta De Guzman, Jun Teruya, Vadim Kostousov, Amir Navaei and Olivia Kwan, Baylor College of Medicine, Houston, TX
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune condition defined as the presence of thrombotic events and/or pregnancy morbidity, accompanied by persistent antiphospholipid antibodies (aPLs). Pediatric…
Abstract Number: 0140 • ACR Convergence 2025
Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
Sindhuja Rajendran¹, ashish mathew², sukesh chandran nair³, john mathew² and ruchika goel², ¹Christian Medical College ,Vellore, Madurai, Tamil Nadu, India, ²Christian Medical college , Vellore , India, Vellore, Tamil Nadu, India, ³Christian,Medical College ,Vellore ,India, Vellore, Tamil Nadu, India
Background/Purpose: Non-criteria manifestations occur in 24% in Primary antiphospholipid syndrome (PAPS) . The efficacy of immunosuppressants in patients with above condition is not certain due…
Abstract Number: 0124 • ACR Convergence 2025
Single-cell atlas reveals the central-and-peripheral immune remodeling mechanism and clinical benefits of talitacicept therapy in patients with primary antiphospholipid syndrome
Haoyu Pan¹, Shiyan Gu¹, Xiaohan Wei², Yuying Fan¹, Jinyi Qian¹, Shuyi Yu¹ and Hui Shi³, ¹Department of Rheumatology and Immunology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Shanghai, Shanghai, China (People's Republic), ²Shanghai JiaoTong University, Shanghai, China (People's Republic), ³Shanghai Jiaotong University Affiliated Ruijin Hospital, Shanghai, China (People's Republic)
Background/Purpose: To elucidate the molecular and cellular mechanisms underlying Talitacicept therapy in primary antiphospholipid syndrome (PAPS) patients using integrated single-cell RNA and TCR/BCR profiling of…
Abstract Number: 1284 • ACR Convergence 2025
Clinical implications of Antiphospholipid Antibodies and Secondary Antiphospholipid Syndrome in Juvenile-onset Systemic Lupus Erythematosus
Daniel Clemente¹, Alina-Lucica Boteanu², Clara Udaondo³, Joan Calzada⁴, Juan Carlos Nieto⁵, Eugenia Enriquez⁶, Inmaculada Calvo⁷, Lourdes Villalobos⁸, Belen Sevilla⁹, Sara Murias¹⁰, Berta Magallares¹¹, Ana Capilla¹², Jaime Arroyo¹³, Beatriz Bravo¹⁴, Gisela Diez-Cordoves¹⁵, Marisol Camacho¹⁶, Genaro grana¹⁷, Juan Jose Bethencourt¹⁸, Pablo Mesa¹⁹, Natalia Palmou²⁰, Mireia Lopez Corbeto²¹, Judith Sanchez²², Maria Isabel Gonzalez²³, Clara Moriano²⁴, Diego Dios¹⁷, Lorena Exposito²⁵, Alicia Garcia²⁶, Laura Martin²⁷, David Fernandez²⁸, Laura Trujillo¹⁴, Anahy Maria Brandy²⁹, CARLOS GUILLEN-ASTETE³⁰ and lydia Abasolo Alcazar³¹, ¹Hospital Infantil Universitario NIño Jesús, Madrid, Madrid, Spain, ²H.U. Ramón y Cajal, Madrid, Spain, ³La Paz University Hospital, Madrid, Spain, ⁴University Hospital Sant Joan de Deu, Barcelona, Spain, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Clínica Universidad de Navarra, Madrid, Spain, ⁷Hospital La Fe, Valencia, Comunidad Valenciana, Spain, ⁸Ramon y Cajal Hospital, MADRID, Spain, ⁹Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ¹⁰H.U Central de Asturias, Oviedo, Spain, ¹¹Hospital de Sant Pau, Bareclona, ¹²H.U de La Merced, Sevilla, Spain, ¹³HOSPITAL UNIVERSITARIO LA PAZ, MADRID, ¹⁴H.U Virgen de Las Nieves, Granada, Spain, ¹⁵H. R. U. Malaga, Malaga, Spain, ¹⁶H.U. Virgen del Rocío, Sevilla, Spain, ¹⁷H.U de A Coruña, A Coruña, Spain, ¹⁸H.U. Canarias, Canarias, Spain, ¹⁹H.U Virgen de la Arrixaca, Murcia, Spain, ²⁰H.U. marques de Valdecilla, Santander, Spain, ²¹H.U Vall d´Hebron, Barcelona, Spain, ²²Pediatric Rheumatology Department, Taulí Hospital Universitari-Institut d'Investigació i Innovació Parc Taulí (I³PT-CERCA), Sabadell (Spain)., Sabadell, Spain, ²³H.U. La Fé, Valencia, Spain, ²⁴Hospital León, LEON, Castilla y Leon, Spain, ²⁵H.U Canarias, Canarias, Spain, ²⁶Rheumatologist, La Laguna, Spain, ²⁷H.R.U Malaga, Malaga, Spain, ²⁸Complejo Hospitalario Universitario de Vigo, Vigo, Galicia, Spain, ²⁹Hospital Germans Trias i Pujol, Badalona, Spain, ³⁰H.U Ramón y Cajal, Madrid, Spain, ³¹IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Antiphospholipid antibodies (aPL) have been associated with organ damage and certain features in juvenile-onset systemic lupus erythematosus (jSLE) patients. We aimed to assess the…
Abstract Number: 0138 • ACR Convergence 2025
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Sami Rabah and Xiangyi Kang, Lincoln Medical Center, New York, NY
Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…
Abstract Number: 0122 • ACR Convergence 2025
The role of low profile antiphospholipid antibodies and adverse pregnancy outcomes.
Eugenia Chock¹, Tong Wang², Areeka Memon³, Zeyan Liew⁴ and Pengfei Guo⁴, ¹Yale School of Medicine, New Haven, CT, ²Yale School of Public Health, New Haven, ³Yale New Haven Health, New Haven, CT, ⁴Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven
Background/Purpose: Presence of high titer antiphospholipid antibodies (aPLs) confer adverse pregnancy outcomes (APOs). Patients with low titer aPLs often receive conflicting counseling on treatment, many…
Abstract Number: 0933 • ACR Convergence 2025
Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Yunwei Xia¹, Paul Hoover², Arnon Arazi³ and Anne Davidson¹, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Brigham and Women's Hospital, Boston, MA, ³Feinstein Institutes for Medical Research, Acton, MA
Background/Purpose: TLR8 has been implicated in adverse outcomes of human pregnancy. We previously reported a mouse model of spontaneous aPL-induced pregnancy loss in Sle1 mice…
Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
RITESH KUMAR MISHRA¹, SUBIN PHILIP², JAIDEV MENON², RIZWANA NAUSHAD², AISHWARYA GOPAL³, CHRISTINA MARIASELVAM², Chengappa Kavadichanda², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…
Abstract Number: 0121 • ACR Convergence 2025
The Prevalence and Clinical Significance of IgA Anticardiolipin and Anti-β2-Glycoprotein-I Antibody Isotypes in Antiphospholipid Antibody Positive Patients: Descriptive Results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking Registry
Emre Sahin¹, Yu (Ray) Zuo², Danieli Andrade³, Maria Tektonidou⁴, Vittorio Pengo⁵, Massimo Radin⁶, Chary López pedrera⁷, Diana Paredes-Ruiz⁸, H Michael Belmont⁹, Paul Fortin¹⁰, Denis WAHL¹¹, Ware Branch¹², Maria Gerosa¹³, Guilherme Ramires de Jesus¹⁴, Tatsuya Atsumi¹⁵, Maria Efthymiou¹⁶, Angela Tincani¹⁷, Esther Rodriguez-Almaraz¹⁸, Michelle Petri¹⁹, Ricard Cervera²⁰, Rohan Willis²¹, Katrien Devreese²², Maria Laura Bertolaccini²³, Hannah Cohen²⁴, Jason S. Knight² and Doruk Erkan¹, ¹Hospital for Special Surgery, New York, NY, ²University of Michigan, Ann Arbor, MI, ³University of Sao Paulo, São Paulo, São Paulo, Brazil, ⁴National and Kapodistrian University of Athens, Athens, Greece, ⁵Padova University Hospital, Padova, Italy, ⁶University of Turin, Turin, Turin, Italy, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Spain, ⁸Biobizkaia Health Research Institute, Barakaldo, Spain, ⁹NYU School of Medicine, New York, NY, ¹⁰Centre ARThrite - CHU de Québec - Université Laval, Quebec, QC, Canada, ¹¹University of Lorraine, Nancy, France, ¹²University of Utah Health Sciences Center, Salt Lake City, UT, ¹³University of Milan, Milano, Italy, ¹⁴Universidade do Estado do Rio de Janeiro, Rio De Janeiro, Rio de Janeiro, Brazil, ¹⁵Hokkaido University, Sapporo, Japan, ¹⁶University College London, London, United Kingdom, ¹⁷ASST Spedali Civili-University of Brescia, Gussago, Brescia, Italy, ¹⁸Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹⁹Johns Hopkins University School of Medicine, Timonium, MD, ²⁰Hospital Clinic Barcelona, Barcelona, Spain, ²¹University of Texas Medical Branch, Galveston, TX, ²²Ghent University, Gent, Belgium, ²³King's College London, London, United Kingdom, ²⁴University College London Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: The 2023 ACR/EULAR Antiphospholipid Syndrome (APS) Classification Criteria (CC) focus on IgG and IgM anticardiolipin (aCL) and anti-β2-glycoprotein-I antibodies (aβ2GPI). IgA isotypes were excluded…
Abstract Number: 0710 • ACR Convergence 2025
Vascular Events in Systemic Sclerosis Patients with Anti-Phospholipid Antibodies
Vivian Shing¹, Emily Thompson², Emma Terwilliger³, Simran Ravindra Nimal⁴, Alejandro Diaz Arumir Vergara², Michael Pham⁴ and Vivek Nagaraja⁴, ¹Mayo Clinic Alix School of Medicine, Scottsdale, AZ, ²Mayo Clinic, Scottsdale, ³Mayo Clinic Alix School of Medicine, Scottsdale, ⁴Mayo Clinic, Scottsdale, AZ
Background/Purpose: APS is a pro-thrombotic autoimmune condition often associated with other systemic autoimmune rheumatic diseases (SARDs), most notably SLE. The link between aPL positivity and…
Abstract Number: 0136 • ACR Convergence 2025
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
RITESH KUMAR MISHRA¹, SUBIN PHILIP², RIZWANA NAUSHAD², AISHWARYA GOPAL³, Chengappa Kavadichanda², CHRISTINA MARIASELVAM², RAJESH N G², Molly mary Thabah³ and VIR SINGH NEGI², ¹JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, Bhubaneswar, India, ²JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, Puducherry, India, ³JAWAHARLAL INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH, PUDUCHERRY, India
Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of…
Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Elizabeth Sloan¹, Blake Baay², Lynnette Walters², Paola Sparagana², Kristina Ciaglia¹, Simrat Morris¹, Julie Fuller¹, Lorien Nassi¹, Tracey Wright¹ and Ayesha Zia³, ¹UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, ²Scottish Rite for Children, Dallas, TX, ³UT Southwestern and Children's Medical Center, Dallas, TX
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].